Blueprint Investment Partners LLC Acquires 2,537 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Blueprint Investment Partners LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 59.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,771 shares of the biopharmaceutical company's stock after purchasing an additional 2,537 shares during the period. Blueprint Investment Partners LLC's holdings in Gilead Sciences were worth $625,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 154 shares in the last quarter. YANKCOM Partnership bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $28,000. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the 4th quarter worth $31,000. Finally, Stephens Consulting LLC increased its holdings in Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares during the period. Institutional investors own 83.67% of the company's stock.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the company from $80.00 to $120.00 in a research note on Tuesday, February 18th. Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research note on Tuesday, March 4th. Morgan Stanley boosted their price target on Gilead Sciences from $123.00 to $130.00 and gave the company an "overweight" rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research report on Thursday. Finally, BMO Capital Markets upped their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $105.12.

Remove Ads

Gilead Sciences Stock Performance

GILD traded up $1.89 on Thursday, hitting $111.16. The company's stock had a trading volume of 6,382,732 shares, compared to its average volume of 6,806,689. The company's 50 day simple moving average is $105.08 and its 200-day simple moving average is $94.58. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The firm has a market cap of $138.43 billion, a P/E ratio of 300.43, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.84%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.